CALGARY, AB / ACCESSWIRE / March 30, 2017 / Fanlogic Interactive Inc. (TSX-V: FLGC), “Fanlogic or the Company”) is pleased to announce that Dream Factory and Cratos Global have been retained to work on all aspects of brand development including, advertising, marketing and supporting business development strategic objectives.

Initial work will center on business transformation, leveraging the past successes of Fanlogic. The team will focus on brand development and re-branding the new company including messaging, tradeshow development, video production, and infographics as well as creating and executing Fanlogic’s campaigns and strategies. Dream Factory will focus on increasing results through better ROI transparency for clients. “Our focus, in the wake of our partnership agreement with Dream Factory and Cratos Global is to drive client value in the U.S.A. and Canada. The signing of this agreement gives us proven partners in communicating our value proposition,” said Fanlogic CEO, Randolph Brownell.

Dream Factory’s CEO, Paulo Cigagna, added, “To establish a clear brand in the proper global context requires businesses to migrate their company’s brand, familiarize themselves with the target audience and work with an experienced partner to bridge markets in Canada and the U.S.A.” Mr. Cigagna continued, “In today’s market, it is irresponsible to make expensive decisions based on hunches. Companies need strategies that not only deliver results, but also deliver high quality data to improve results over time. We’re working with Fanlogic to accelerate this critical integration process, enabling Fanlogic to launch products, service offerings and new brand messaging quicker and more effectively.”

Fanlogic’s offerings include, contests, coupons, display advertisements, direct-buy offers, 50/50 charity draws and social fantasy games.

About Fanlogic:

Fanlogic is a leader in providing digitally driven contests and social fantasy games that provide brands with cutting edge user data and insights. Brands benefit from this unique data by leveraging higher quality lead generation, social engagement, brand exposure, and conversion rates.

Our digital lead and sales generation success is driven through our proprietary peer to peer referral based contests, coupons, sweepstakes, charitable initiatives, branded games, 50/50 lotteries, loyalty & incentives and daily fantasy sports and entertainment contests.

For more information about Fanlogic, visit http://www.fanlogic.com

About Dream Factory:

Founded in 1999, Dream Factory is a full-service agency that provides tailored and comprehensive marketing strategies, branding efforts, lead generation, sales support and more through a transparent process that feeds seamlessly into each client’s operations, propelling brand influence and corporate growth.

For more information about Dream Factory, visit http://www.dreamfactoryagency.com

About Cratos Global:

At the core of our company DNA is a process driven approach. Bringing the right processes together involves a deliberate strategy customized for each client. Whether it is product development, marketing, advertising, or public relations (PR), Cratos Global’s process utilizes dynamic approaches, comprehensive industry and company understanding, and the most progressive technologies. Our stakeholder driven collaboration methodology helps uncover ideas, analyze market, competitive risks and opportunities, and, then, detail the best plan to meet the challenges of your strategic objectives. Results are perceptible, significant and cost effective.

For more information about Cratos Global, visit http://www.cratosglobal.com/communications/.

Randy Brownell
rbrownell@fanlogic.com
CEO
(540) 208-7700

Rob Danard
rob@fanlogic.com
President
(403) 614-4441

Reader Advisory

Certain information set forth in this news release contains forward-looking statements or information (“forward-looking statements”), including details about the business of the Corporation and the use of proceeds from the Offering. By their nature, forward-looking statements are subject to numerous risks and uncertainties, some of which are beyond the Corporation’s control, including the impact of general economic conditions, industry conditions, volatility of commodity prices, currency fluctuations, environmental risks, operational risks, competition from other industry participants, stock market volatility, and the ability to access sufficient capital from internal and external sources. Although the Corporation believes that the expectations in its forward-looking statements are reasonable, its forward-looking statements have been based on factors and assumptions concerning future events which may prove to be inaccurate. Those factors and assumptions are based upon currently available information. Such statements are subject to known and unknown risks, uncertainties and other factors that could influence actual results or events and cause actual results or events to differ materially from those stated, anticipated or implied in the forward-looking statements. Accordingly, readers are cautioned not to place undue reliance on the forward-looking statements, as no assurance can be provided as to future results, levels of activity or achievements. Risks, uncertainties, material assumptions and other factors that could affect actual results are discussed in our public disclosure documents available at www.sedar.com. Furthermore, the forward-looking statements contained in this document are made as of the date of this document and, except as required by applicable law, the Corporation does not undertake any obligation to publicly update or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise. The forward-looking statements contained in this document are expressly qualified by this cautionary statement. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

SOURCE: Fanlogic

ReleaseID: 458555

NEW YORK and LONDON / ACCESSWIRE / March 30, 2017 / WeConvene, a global and fully independent corporate access platform, is introducing extended features that will give sell-side Analysts the tools to thrive in a post-MiFID II world.

WeConvene’s platform enables buy-side and sell-side firms to collaborate online for the efficient management of all their corporate access and analyst marketing interactions in a single place.

On March 28, WeConvene announced the successful close of its Series B financing, proceeds of which are going to be used for product development, among other things. Today’s announced features enable entire research teams to quickly and easily manage all their interactions and marketing schedules with the buy-side. From creating and booking meetings online, to the promotion of their profile (including industry awards, e.g. Extel ranking), so clients can accurately justify the allocation of research funds. The WeConvene platform delivers an innovative solution which addresses and supports the unbundling requirements of MiFID II across the financial community.

Commenting on the new product features, CEO, Radek Barnert, said “MiFID II presents many challenges to our clients. One such challenge is monetizing Analyst time and availability under the new rules. We have added analyst workflow to enable sell-side research teams to do just that, by directly connecting them to the largest buy-side audience globally.”

With MiFID II approaching, many sell-side firms are working to establish a model for charging for analyst time. To support this change, firms will need to ensure all interactions are accurately captured and transparent to clients for billing. Likewise, as we move to a monetized approach, buy-side firms need a way to objectively evaluate the quality of analyst services and ensure budget is spent on the most valuable meetings.

“Under MiFID II, buy-side firms will cast a critical eye over what research is paid, which is likely to lead to a ‘fight to quality,'” says Joseph Connelly, Global Head of Product at WeConvene. “Analysts will face increased pressure to demonstrate their value in what is likely to become a highly competitive environment. The visibility of how their time is spent, along with their credentials (to promote their value to clients), will become critical.”

The key features of WeConvene’s Analyst Access workflow include:

Connect with the world’s largest buy-side audience

Create events, meetings, or calls and manage all bookings online.
Promote your availability with clients and effectively manage incoming requests.
View detailed reports of all interactions with clients in real-time.

Promote and market your services

Create a detailed biography to promote the sectors and markets covered, as well as the inclusion of relevant survey rankings, e.g. Extel Survey, and career highlights.

Automated consumption tracking and evaluation tools

At a firm level, have a complete picture of all Analyst interactions and customize to your needs, e.g. Analyst comparisons, meeting type, client type, location, etc.

About WeConvene

WeConvene is a global web-based platform designed to eliminate the inefficiencies of managing the corporate access process for the investment community. Events large and small can impact investment strategies and WeConvene provides value to both buy- and sell-side customers by enabling efficient discovery, booking, and tracking of meetings. For more information, visit www.weconvene.com or request a demo by contacting sales@weconvene.com.

Media Contact

Sarah Linfoot

sarah@weconvene.com

SOURCE: WeConvene Limited

ReleaseID: 458466

NEW YORK, NY / ACCESSWIRE / March 30, 2017 / CombiMatrix and Vertex Pharmaceuticals have made investors optimistic about the future of their companies as both stocks find broader markets for their products. Both companies saw 15 to more than 20 percent rises in their stock prices, with Vertex continuing to show strength in after hours trading.

RDI Initiates
Coverage:

CombiMatrix Corp. https://ub.rdinvesting.com/news/?ticker=CBMX

Vertex
Pharmaceuticals Inc. https://ub.rdinvesting.com/news/?ticker=VRTX

CombiMatrix advanced 17.71% to close at $5.65 on Wednesday. The stock traded between $5.75 and $4.75 on volume of 677,574 shares traded. CombiMatrix reported its fourth quarter and full year 2016 results on February 22nd, where unit sales volume increased by 10% in year 2016 whereas revenue increased roughly 27% in year 2016. These numbers suggest that the sales are driven by pricing power. The company focuses on pre-implantation generic screening, miscarriage analysis, prenatal confirmatory diagnosis and pediatric developmental disorders. There has been little slowdown in the overall industry’s growth over the last decade. Mark McDonough, CombiMatrix President and CEO, said on the fourth quarter result: “Total revenues for the quarter increased 32% year-over-year to $3.5 million, driven by record reproductive health test volume and revenues, and across-the-board increases in average revenue per test.”

With this result, CombiMatrix has narrowed down its quarterly and yearly losses with the fourth quarter loss of $558,000 or $0.22 a share for fourth quarter of 2016 as compared to loss of $1.7 million or $2.02 reported in the same quarter of 2015.

Access RDI’s CombiMatrix Research Report at: https://ub.rdinvesting.com/news/?ticker=CBMX

Vertex Pharmaceuticals advanced 20.45% to close at $108.01 on Wednesday. The stock traded between $111.88 and $106.03 on volume of 13.68 million shares traded. The company is seeking approval for its experimental Cystic-Fibrosis drug and plans to file for both U.S. and European approval for the combination of its products tezacaftor and ivacaftor sometime in the 3rd quarter of this year, as Vertex has released positive result of Phase 3 studies on March 28th. It is also expected that the decisions for the approval is likely to take place sometime in the first half of 2018.

Two Phase III studies of their Tezacaftor/Ivacaftor combination treatment have met primary FDA Endpoints, and there are measurable, statistically significant improvements reported in Lung Function in people with Cystic Fibrosis. CMO Jeffrey Chodakewitz said, “The tezacaftor/ivacaftor combination treatment demonstrated clinically meaningful benefits, with a favorable safety profile, across multiple patient groups.”

Access RDI’s Vertex Pharmaceuticals Research Report at: https://ub.rdinvesting.com/news/?ticker=VRTX

Our Actionable Research on CombiMatrix Corp. (NASDAQ: CBMX) and Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) can be downloaded free of charge at Research Driven Investing.

Research Driven
Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 458554

NEW YORK, NY / ACCESSWIRE / March 30, 2017 / The two famous retailers have found supporters among the investment community to make their stocks worth a second look as both companies struggle to keep in the black. Sears found believers from within, while JC Penney, a stock that somehow always seems it is on the ropes, gained interest.

RDI Initiates
Coverage:

Sears Holdings Corp. https://ub.rdinvesting.com/news/?ticker=SHLD

JC Penney Company
Inc. https://ub.rdinvesting.com/news/?ticker=JCP

Sears Holdings Corp. advanced 1.77% to close at $11.50 on Wednesday. The stock traded between $12.67 and $11.01 on volume of 5.2 million shares traded. Recent advances in this week took investors by surprise, as the company announced as recently as last week that unless its sales would dramatically improve or that reorganization of its debt by its creditors could be arranged, the company would have to file for bankruptcy. Only a few days ago the company essentially admitted it would close down 150 stores.

The Company’s biggest shareholders Edward Lampert and Fairholme Capital stepped in to increase their stakes in the business, contrary to the justified concerns over the retailer’s future. The insider buying after the 12% drop the company took on March 22nd, is a sign investors should pay close attention to. A point that was not given much press in the same filing with the SEC stated that, “The Company said in the filing, however, that it believed the actions it has been taking would likely mitigate that substantial doubt.” While a mitigation may not equal a resolution, the stock may be a bargain for the short term.

Access RDI’s Sears Holdings Research Report at: https://ub.rdinvesting.com/news/?ticker=SHLD

JC Penney advanced 5.35% to close at $6.10 on Wednesday. The stock traded between $6.30 and $5.76 on volume of 34.85 million shares traded. What can be described as “Sears in Reverse,” the company had announced in February its first annual profit since 2010 along with the closure of underperforming stores. The combination of moving into the blank spaces vacated by Sears and reducing expenses can be attributed in part to the day’s price rise. Yet investors, perhaps with good reason, avoided committing to the company.

Standard & Poor’s upgraded the credit rating of JC Penney on Monday, March 13th. Its new rating is B-plus. The price of the stock on that date fell 5.82% to $5.99 a share. The company currently has over 1,000 operational stores. Given the current status of the retail industry, the question that still remains in the minds of investors is whether JC Penney is a bargain or a long term loss.

Access RDI’s JC Penney Research Report at: https://ub.rdinvesting.com/news/?ticker=JCP

Our Actionable Research on Sears Holdings Corp. (NASDAQ: SHLD) and JC Penney Company Inc. (NYSE: JCP) can be downloaded free of charge at Research Driven Investing.

Research Driven
Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 458557

NEW YORK, NY / ACCESSWIRE / March 30, 2017 / The two companies posted nice gains as each company is showing signs of bringing their product to market as their products garner the attention of investors and peers alike. Tonix has broken through one barrier as their Phase III trial begins, while Athersys gains the attention of a professional, peer-reviewed journal.

RDI Initiates
Coverage:

Tonix Pharmaceuticals
Holding Corp. https://ub.rdinvesting.com/news/?ticker=TNXP

Athersys, Inc. https://ub.rdinvesting.com/news/?ticker=ATHX

Tonix Pharmaceuticals advanced 34.54% to close at $5.47 on Wednesday. The stock traded in a wide range, bouncing between $9.40 and $5.45 a share on a very large volume of 30.35 million shares traded. On March 28th, Tonix, a company that develops drugs for common central nervous system disorders, has enrolled its first participant in a military related PTSD Phase 3 HONOR Trial of its breakthrough drug. The drug, TNX-102 SL, a drug designed for the treatment of post-traumatic stress disorder (PTSD) has been recently granted the status of Breakthrough Therapy by the U.S. Food and Drug Administration (FDA). The company has been invited to present its FDA Breakthrough Therapy drug at The MicroCap Conference, to be held in New York City on April 4th of this year.

Earlier on March 27th, Tonix performed a reverse stock split exercise of 1-for-10 on its outstanding stocks, to comply with the NASDAQ rules. Tonix has narrowed its losses to $7.6 million in the third quarter of 2016 as compared to loss of $13.25 million reported in the same period in 2015. Reported cash assets as on September 30th were $26.7 million and on March 29th, Tonix announced proposed public offering of common stock, the proceed from which will be used for the further development of TNX-102 SL and other drugs in the pipeline and to improve its cash positions and working capital.

Access RDI’s Tonix Pharmaceuticals Research Report at: https://ub.rdinvesting.com/news/?ticker=TNXP

Athersys advanced 22.03% to close at $1.44 on Wednesday. The stock traded between $1.52 and $1.29 on a higher volume of 11.4 million shares traded. MultiStem is used to treat patients who have suffered an ischemic stroke, which accounts for an estimated more than 80% of all strokes. Athersys is actively involved in research and development in the field of regenerative medicine.

Its MultiStem cell therapy product, is a patented, for off-the-shelf, human stem cell product that was initially intended for disease indications in the neurological, cardiovascular, inflammatory and immune disease areas. The company has expanded the application to several ongoing clinical trials, evaluating its potential regenerative properties in other areas. For investors, Athersys has worked to develop strategic partnerships with some of the world’s leading pharmaceutical and biotechnology companies. In addition, they have collaborated with select world-renowned research institutions to further assist in the development of both its platform and related products.

Athersys has reported a loss of $7.13 million or $0.1 a share on revenue of $1 million for the fourth quarter of 2016 as compared to profit of $3.6 million or $0.04 a share on revenue of $10.6 million reported in the same quarter of 2015. The decline in year-on-year revenue was mainly because Athersys had received license fee of $10.0 million in the fourth quarter of 2015 from Chugai Pharmaceuticals on termination of contract. On March 10th, Athersys announced mixed shelf offering of up to $75 million.

Access RDI’s Athersys Research Report at: https://ub.rdinvesting.com/news/?ticker=ATHX

Our Actionable Research on Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) and Athersys, Inc. (NASDAQ: ATHX) can be downloaded free of charge at Research Driven Investing.

Research Driven
Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com

ReleaseID: 458553

MONTREAL, QC / ACCESSWIRE / March 30, 2017 / IOU FINANCIAL INC. (“IOU” or the “Company”; TSX-V: IOU), a leading online lender to small businesses (IOUFinancial.com), is pleased to announce its CEO, Philippe Marleau, will present at this year’s The MicroCap Conference (“the Conference”) on April 4th in New York City.

The Conference is an exclusive event for investors who specialize in small and microcap stocks to be introduced to and speak with management at some of the most attractive small companies, learn from various expert panels, and mingle with other microcap investors. The Conference does not allow service providers – only portfolio managers, analysts, and private investors.

About IOU Financial

IOU provides small businesses throughout the U.S. and Canada access to the capital they need to seize growth opportunities quickly. Typical customers include medical and dental practices, grocery and retail stores, restaurant and hotel franchisees, and e-commerce companies. In a unique approach to lending, the IOU Financial advanced, automated application and approval system accurately assesses applicants’ financial realities, with an emphasis on day-to-day cash flow trends. It makes loans of up to US$150,000 to qualified U.S. applicants ($100,000 in Canada) within a few business days, with affordable charges favorable to cash-flow management. Its speed and transparency make IOU Financial a trusted alternative to banks. To learn more, visit: IOUFinancial.com.

About The MicroCap Conference

Registration for investors – to register, please click “Register” on our website microcapconf.com.

Participating companies – for our most updated list of companies, please go to our website (http://microcapconf.com/conferences/new-york-2017/).

MARQUEE SPONSORS

The Special Equities Group
Maxim Group

News compliments of ACCESSWIRE.

FOR MORE INFORMATION

Please visit: www.microcapconf.com.

Or, contact Tony Yu at tony@microcapconf.com.

Forward-Looking Statements

Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of IOU including, but not limited to, the impact of general economic conditions, industry conditions, dependence upon regulatory and shareholder approvals, the execution of definitive documentation and the uncertainty of obtaining additional financing. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. IOU does not assume any obligation to update or revise its forward-looking statements, whether as a result of new information, future events, or otherwise.

The TSX-V has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

For more information, please contact:

Philippe Marleau
Chief Executive Officer
+1 (514) 789-0694 ext. 225

Benjamin Yi
Corporate Development & Investor Relations
+1 (647) 295-0654

SOURCE: IOU Financial Inc.

ReleaseID: 458480

Fintech Company Provides Proprietary and Innovative Mobile Payment Solution Across Multiple Industries

DENVER, CO / ACCESSWIRE / March 30, 2017 / CannaSys, Inc. (OTC PINK: MJTK), a marketing, branding, and technology company, signed a letter of intent to acquire Alliance Financial Network, Inc. (“AFN”). AFN is a Colorado-based financial technology (Fintech) company that provides a unique, proprietary digital transaction and mobile payment solution. AFN, a federally registered financial institution, has developed, owns and operates eXPO™, its electronic eXchange POrtal.

eXPO™ provides access for consumers and businesses to transfer funds electronically, whether consumer-to-consumer, consumer-to-business, business-to-consumer or business-to-business. eXPO™ delivers electronic payment solutions to multiple industries. AFN is currently working with companies in a number of vertical markets that can leverage the eXPO system immediately because of its universally compliant foundation and its ability to be scaled rapidly.

AFN’s proprietary eXPO™ technology facilitates transactions between members inside the eXPO™ network, and between network members and those outside the network, to address those served by traditional, as well as non-banked, under-banked and cash intensive industries. eXPO™ members include consumers, businesses, and governmental agencies. eXPO™ has the ability to accurately track and report local, state, and if applicable, federal tax obligations of consumers and retailers. eXPO™ can be found at www.getexponow.com.

AFN and eXPO™ are registered with the U.S. Department of the Treasury Financial Crimes Enforcement Network (FinCEN) as a financial institution. This registration provides AFN with the appropriate regulatory framework and guidance on a federal level for Bank Secrecy Act (BSA) and Anti-Money Laundering (AML) compliance. The eXPO™ mobile application is downloadable by consumers and businesses once they become an eXPO™ member.

CannaSys will acquire AFN by issuing a controlling equity stake in the proforma company, whereby AFN will become a wholly owned CannaSys subsidiary. The combined company will market AFN’s products, and platforms, as well as the CannaSys suite of products. As part of the transaction, AFN’s nominees will become directors and key officers of CannaSys, and the Cannasys, Inc. name will be changed to Alliance Financial Network, Inc. On February 12, 2017, CannaSys solidified its commitment to closing the transaction with a direct investment in AFN.

“I could not be more excited about AFN’s core products, its management team, and its exponential growth prospects across multiple industries,” commented CannaSys CEO, Michael Tew. “eXPO™ was created to meet the demands of a changing landscape within the payments industry, and it demonstrates how the fintech sector continues to introduce revolutionary product offerings.”

In addition to the controlling interest issued to AFN as part of the transaction, AFN will be eligible to earn additional shares for meeting certain performance targets based upon the rollout of its core eXPO™ technology within the next two years. The metrics for the earn-out are the following:

1. Executed agreement or contracts that use AFN’s technology and/or platform and result in projected revenue of $5 million in the following 12 months; or
2. Executed agreement or contracts with commercially reasonable terms that result in the deployment of AFN’s technology in more than 250 retailers over the following 12 months.

“The earn-out targets are a cornerstone of AFN’s alignment with shareholders and further demonstrates AFN’s conviction regarding its products and business strategy,” commented Tew.

Larry Lipman, AFN CEO and Founder, noted: “Our transaction with CannaSys is accretive to AFN’s discussions with regulators and retailers. We have already made substantial progress in delivering a valuable regulatory-compliant product to the marketplace. Now we are focused on accelerating growth opportunities in the upcoming year.”

Completion of the AFN acquisition is contingent on a number of factors, including the execution of a definitive acquisition agreement, compliance with representation and warranties, the satisfaction of specified conditions, and other matters.

About CannaSys, Inc.

CannaSys is a technology solutions, marketing, and branding company. Its core products are delivered “software as a service” to facilitate point-of-purchase transactions, customer relationship marketing solutions. CannaSys plans to develop, acquire, and build strategic relationships with other businesses in order to bring additional solutions to market. For more information, please visit www.cannasys.com

About Alliance Financial Network, Inc.

Alliance Financial Network, Inc. (AFN) is a federally registered financial institution that owns and operates eXPO™, a mobile payment solution that has the ability to track product inventory, delivery and generate audit-ready reports. AFN conducts compliance reviews on all clients. These reviews are designed to meet financial industry standards for know-your-customer requirements and regulatory reporting. In addition to AFN’s inventory-to-general-ledger tracking system, the company features access to federally licensed, secure and compliant cash transport, which also includes storage (vaulting) and delivery to the Federal Reserve.

AFN’s enterprise end-to-end ecosystem enables licensed users to interact in a secure, transparent environment. This unique system enforces compliance at every step, ensuring clear and connected tracking for regulatory audits and accounting purposes. AFN believes its eXPO™ product will become the gold standard for industry compliance and mobile payment solutions.

FORWARD-LOOKING STATEMENTS

This release includes forward-looking statements. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including continued acceptance of CannaSys’s products, increased levels of competition for CannaSys, new products and technological changes, CannaSys’s dependence on third-party suppliers, and other risks detailed from time to time in CannaSys’s periodic reports filed with the U.S. Securities and Exchange Commission.

CannaSys, Inc.
Michael A. Tew
Chief Executive Officer
Tel: 720.420.1290
Email: michael.tew@cannasys.com
Web: www.cannasys.com

SOURCE: CannaSys, Inc.

ReleaseID: 458569

NEW YORK, NY / ACCESSWIRE / March 30, 2017 / SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, today announced it has issued an update on Lomiko Metals, Inc. (TSXV: LMR.V) (OTCQX: LMRMF) (FSE: DH8C).

The report is available here: LMR Update Note.

Based in Vancouver, BC, Lomiko Metals, Inc. (TSXV: LMR.V) (OTCQX: LMRMF) (FSE: DH8C) (“Lomiko”) is an exploration-stage company engaged in the acquisition, exploration and development of resource properties that contain minerals for the new green economy, specifically graphite. In addition to developing high quality graphite plays, including the La Loutre Crystalline Flake Graphite Property and the Quatre Milles Graphite Properties in Quebec, Lomiko is pursuing synergistic growth opportunities in the technology and new energy markets, which leverage its position in the manufacturing graphene, a graphite derivative up to 200x stronger than structural steel that also possesses very high thermal and electrical conductivity properties. These opportunities include the 3D printing, lithium batteries, LED drivers and power conversion products.

Update on drilling results from La Loutre

On March 7, 2017, Lomiko and partner Canada Strategic Metals (TSX.V: CJC) announced encouraging drilling results for high grade graphite from the refractory zone in the La Loutre property north of Montreal. In the joint press release, the companies defined an area of mineralization that appears to be 200 meters wide, with a current strike length of 400 meters in a northwest to southeast direction, which is open from both directions. The announcement is a continuation of encouraging drilling results for the play, which management indicated has shown “excellent” data including near-surface, high grade flake graphite, helping further define its potential. We note that the identification of high purity graphite crystalline flake can serve as the base material for testing graphite for the ultrapure carbon market, for anode materials used in lithium-ion batteries and for conversion into graphene for use in 3D printers and supercapacitors. We have included detailed results of the latest announcement, and note that the company is planning to complete a Pre-economic Assessment (PEA) during calendar 2017.

Spider Charger™ advancing

Lomiko’s wholly owned subsidiary, Lomiko Technologies, appears to be nearing commercialization for its innovative new Spider Charger™, an in-wall USB charging device that employs a sleek design while improving energy efficiency for customers and allowing up to eight electronic devices (two standard, 6 via USB ports) to charge safely at one time. The Spider Charger™ was developed as a result of technology acquired through Lomiko’s December 2014 licensing agreement with Megahertz Power Systems Ltd. The companies then formed a joint venture, SHD, in 2016 to focus on the development of IoT (“internet of things”) devices, beginning with the Spider Charger. There is clearly a large market potential for the Spider Charger™, which has applications for residential and commercial builders, airlines, schools, and businesses with clientele seeking charging stations for their portable electronic devices. In an investor presentation posted to its web site on March 23, 2017, Lomiko detailed 3-year goals for the Spider Charger including revenues of $11.6mn and $2.7mn of operating profit.

Updating target for reverse split

We are updating the target for Lomiko Metals to C$0.75 at this time. The target reflects new shares issued since we initiated coverage on the company, as well as a reverse split in December 2016. We see the company as an intriguing, speculative investment in the graphite and graphene markets, with option-like potential from holdings in its wholly-owned Lomiko Technology subsidiary.

Please review important disclosures on our website at www.seethruequity.com.

About SeeThruEquity

Since its founding in 2011, SeeThruEquity has been committed to its core mission: providing impactful, high quality research on underfollowed smallcap and microcap equities. SeeThruEquity has pioneered an innovative business model for equity research that is not paid for and is unbiased. SeeThruEquity is the host of acclaimed investor conferences that are the ultimate event for publicly traded companies with market capitalizations less than $1 billion.

SeeThruEquity is approved to contribute its research reports and estimates to Thomson One Analytics (First Call), the leading estimates platform on Wall Street, as well as Capital IQ and FactSet. SeeThruEquity maintains one of the industry’s most extensive databases of opt-in institutional and high net worth investors. The firm is headquartered in Midtown Manhattan in New York City.

For more information visit www.seethruequity.com.

Contact:

Ajay Tandon
SeeThruEquity
info@seethruequity.com

SOURCE: SeeThruEquity

ReleaseID: 458568

ORLANDO, FL / ACCESSWIRE / March 30, 2017 / LightPath Technologies, Inc. (NASDAQ: LPTH) (“LightPath,” the “Company,” or “we”), a leading vertically integrated global manufacturer, distributor and integrator of proprietary optical and infrared components and high-level assemblies, announced the addition of glass manufacturing capabilities as part of LightPath’s vertical integration strategy. As40Se60 chalcogenide glass or BD6 is being produced in high volumes in the Orlando, FL facility and can be used in many infrared applications. This also supports the precision diamond turned and coating options available through its subsidiary, ISP Optics.

Jim Gaynor, LightPath’s President & CEO, stated, “We have produced over 500kg of BD6 and have put the glass through extensive qualification processes. LightPath has the capacity to make enough high quality BD6 glass to cover the great demands of precision molded lenses needed for low cost infrared optics applications.”

LightPath’s team of experts will be on hand at the SPIE Defense Commercial and Sensing conference in Anaheim, CA and are scheduled to present on Monday, April 10th. This paper investigates the composition-dependence of PGM-relevant properties for As38Se62 and standard As40Se60 and presents a comparison of molding behavior and lens performance.

Abstract Details

Location: Anaheim Convention Center
Anaheim, California, United States
Convention Center Room 204A

Author(s): Jacklyn Novak, Spencer Novak, Jeremy Huddleston, Alan Symmons, LightPath Technologies, Inc. (United States); Erik Stover, M3 Measurement Solutions (United States)

Paper 10181-24 Compositional dependence of properties and lens performance of As-Se chalcogenide glass

About LightPath Technologies:

LightPath Technologies, Inc. (NASDAQ: LPTH) is a leading global, vertically integrated provider of optics, photonics and infrared solutions for the industrial, defense, telecommunications, testing and measurement, and medical industries. LightPath designs, manufactures, and distributes proprietary optical and infrared components, including molded glass aspheric lenses and assemblies, infrared lenses and thermal imaging assemblies, fused fiber collimators, and gradient index GRADIUM® lenses. LightPath also offers custom optical assemblies, including full engineering design support. The Company is headquartered in Orlando, Florida, with manufacturing and sales offices in New York, Latvia, and China.

LightPath’s wholly-owned subsidiary, ISP Optics Corporation, manufactures a full range of infrared products from high performance MWIR and LWIR lenses and lens assemblies. ISP’s infrared lens assembly product line includes athermal lens systems used in cooled and un-cooled thermal imaging cameras. Manufacturing is performed in-house to provide precision optical components including spherical, aspherical and diffractive coated infrared lenses. ISP’s optics processes allow it to manufacture its products from all important types of infrared materials and crystals. Manufacturing processes include CNC grinding and CNC polishing, diamond turning, continuous and conventional polishing, optical contacting and advanced coating technologies. For more information on LightPath and its businesses, please visit www.lightpath.com.

This news release includes statements that constitute forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding our ability to expand our presence in certain markets, future sales growth, continuing reductions in cash usage and implementation of new distribution channels. This information may involve risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, factors detailed by LightPath Technologies, Inc. in its public filings with the Securities and Exchange Commission. Except as required under the federal securities laws and the rules and regulations of the Securities and Exchange Commission, we do not have any intention or obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts:

Steve Beninato
Executive Director of Global Sales and Marketing
407-382-4003 Ext 310
sbeninato@lightpath.com

Kimberly Clifton
Director of Sales Operations and Marketing
407-382-4003 Ext 337
kclifton@lightpath.com

SOURCE: LightPath Technologies, Inc.

ReleaseID: 458401

Revenue Increased 27% Year Over Year to $72.6 million; Adjusted EBITDA of $4.4 Million for the Year

PLAINVIEW, NY / ACCESSWIRE / March 30, 2017 / Vaso Corporation (“Vaso”) (OTC PINK: VASO) today reported its operating results for the three months and year ended December 31, 2016.

“We are pleased to announce a record revenue of $72.6 million for the fiscal year 2016, a growth of 27% from 2015, which is significant because it was achieved in spite of a revenue decrease in the professional sales service business segment due to lower volume of equipment deliveries,” stated Dr. Jun Ma, President and Chief Executive Officer of Vaso Corporation. “Revenue contributions from our IT, professional sales service, and proprietary equipment segments were respectively 54%, 39%, and 7% in 2016, signifying a diversified and robust enterprise with less dependence on a single source of income.”

“Our IT segment continues to grow and has built a substantial backlog in 2016. The professional sales service segment also saw an increase in deferred revenue resulting from higher order bookings in 2016 than in the previous year. Performance in our proprietary equipment business improved in 2016, as well. Therefore, while we experienced a decrease in net income in 2016 as a result of continued investment in the IT segment and lower commission revenue in the professional sales service segment, we expect to see continued sales growth in 2017 with improved profitability. Our operations continue to generate healthy positive operating cash flow, $5.2 million in 2016 to be specific, further strengthening the Company’s financial position with cash balances of approximately $8 million as of March 24, 2017,” concluded Dr. Ma.

Financial Results for Three Months Ended December 31, 2016

For the three months ended December 31, 2016, revenue decreased 9.8% to $19.3 million from $21.4 million for the same period of 2015, due primarily to the decrease of $2.3 million in revenue in our professional sales service segment as a result of lower volume of equipment deliveries, partially offset by an increase in revenue in our IT segment principally from an increase in sales in the NetWolves business.

Gross profit for the fourth quarter of 2016 decreased 11.0% to $11.2 million, compared with a gross profit of $12.6 million for the fourth quarter of 2015. This decrease is primarily the result of the decrease in revenue in the professional sales service segment resulting in a decrease in segment gross profit of $1.9 million, partially offset by an increase in gross profit in both the IT and equipment segments.

Selling, general, and administrative (SG&A) expenses for the fourth quarter of 2016 increased 5.8% to $10.4 million, compared to $9.9 million for the fourth quarter of 2015. The increase is primarily attributable to an increase in personnel costs in the professional sales service segment. SG&A expenses were 54.1% of revenue in the fourth quarter of 2016, compared to 46.1% of revenue for the same quarter of 2015.

Net income for the three months ended December 31, 2016 was $0.4 million, compared with a net income of $2.7 million for the three months ended December 31, 2015.

Financial Results for Year Ended December 31, 2016

For the year ended December 31, 2016, revenue increased $15.5 million, or 27.2%, to $72.6 million, compared with $57.1 million for the year 2015. Revenue in our IT segment was $39.4 million for the year ended December 31, 2016, compared to revenue of $21.1 million in 2015, mainly as a result of including full-year revenue from NetWolves in 2016 versus only seven months revenue from NetWolves in 2015. Commission revenues in our professional sales service segment decreased by 9.7% to $28.5 million, as a result of lower equipment deliveries compared to 2015. Equipment segment revenue for the year 2016 increased by 6.2% to $4.6 million, compared to $4.3 million in 2015, principally due to an increase in volume of EECP® equipment sales and an increase in sales at our Biox subsidiary.

Gross profit for the year ended December 31, 2016 increased 17.3% to $41.5 million, from $35.4 million in 2015. The increase was due primarily to the inclusion of twelve months of NetWolves operations in 2016 versus seven months in 2015, and to a higher gross profit in our equipment segment, partially offset by a decrease in gross profit in our professional sales service segment resulting from lower commission revenue in this segment as discussed above.

SG&A expenses for the year ended December31, 2016 increased 27.5% to $39.4 million, or 54.3% of revenue, compared with $30.9 million, or 54.2% of revenue, for the same period in 2015. The increase resulted primarily from including the NetWolves operation for twelve months in 2016, compared to seven months in 2015, and an increase in personnel costs in the professional sales service segment. SG&A costs in the equipment segment decreased, as did corporate costs.

For the year ended December 31, 2016, the Company had net income of $0.8 million, or $0.01 per common share, compared with a net income of $3.8 million, or $0.02 per common share, for the year ended December 31, 2015.

Adjusted EBITDA (earnings before interest, taxes, depreciation and amortization, and share-based compensation) was $4.4 million for the year ended December 31, 2016, compared to $5.8 million for the year ended December 31, 2015. The decrease was primarily the result of lower net income in 2016, partially offset by higher depreciation and amortization of intangibles in 2016 compared to 2015.

Net cash provided by operating activities was $5.2 million and $6.5 million for the year ended December 31, 2016 and 2015, respectively. Net cash increased to $7.1 million at December 31, 2016, compared to $2.2 million at December 31, 2015. The increase in cash is the result of cash provided from operations and an increase in borrowings under our lines of credit. As of March 24, 2016, the Company’s net cash was approximately $8 million.

Deferred revenue remains substantial, at approximately $19.4 million as of December 31, 2016, which will be recognized in the future when the underlying equipment or services are delivered and accepted at the customer site. Our shareholders’ equity increased to $12.9 million as of December 31, 2016 from $11.7 million as of December 31, 2015.

Conference Call Information

The Company will host a conference call on Thursday, March 30, 2017 at 10:00 a.m. eastern time featuring presentations by Jun Ma, Ph.D., President and CEO, Peter Castle, Chief Operating Officer, and Michael Beecher, Chief Financial Officer of Vaso Corporation. To join the conference call, please dial 1-877-407-8033 from the U.S. or 1-201-689-8033 internationally. Please call at least five minutes before the scheduled start time. The conference call will also be available via webcast and can be accessed through the Investor Relations section of Vaso’s website, http://www.vasocorporation.com/. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast.

A replay of the conference call will be available approximately two hours after completion of the live conference call at http://www.vasocorporation.com/. To access the dial-in replay of the call, which will be available until April 30, 2017, please dial 1-877-481-4010 or international 1-919-882-2331. All dial-in participants must use the following code to access the call: 10295.

About Vaso

Vaso Corporation is a diversified medical technology company with several distinctive but related specialties: managed IT systems and services, including healthcare software solutions and network connectivity services; professional sales services for diagnostic imaging products; and design, manufacture, and sale of proprietary medical devices.

The Company operates through four wholly owned subsidiaries. Vaso Technology, Inc. provides network and IT services through two business units: VasoHealthcare IT Corp., a national value added reseller of GE Healthcare IT’s Radiology PACS (Picture Archiving and Communication System) software solutions and related services, including implementation, management and support, and NetWolves Network Services LLC, a managed network services provider with an extensive, proprietary service platform to a broad base of customers. Vaso Diagnostics, Inc. d.b.a. VasoHealthcare, provides professional sales services and is the operating subsidiary for the exclusive sales representation of GE Healthcare diagnostic imaging products in certain market segments in the USA. Vasomedical Solutions, Inc., manages and coordinates the design, manufacture, and sales of EECP® Therapy Systems and other medical equipment operations. Vasomedical Global Corpoperates the Company’s overseas assets including China-based subsidiaries (Biox Instruments Co. Ltd. and Life Enhancement Technology Limited), as well as the minority interest in VSK Medical Limited, a marketing and sales company for ECP products in the international market. Additional information is available on the Company’s website at www.vasocorporation.com.

Summarized Financial Information

FOR THE THREE MONTHS ENDED

FOR THE YEAR ENDED

STATEMENTS OF INCOME

December 31,

2016

December 31,

2015

December 31,

2016

December 31,

2015

(In thousands)

(Unaudited)

Revenue

$
19,289

$
21,384

$
72,589

$
57,082

Gross profit

11,227

12,621

41,502

35,367

Operating income

639

2,682

1,564

3,939

Other income (expense), net

(129
)

(120
)

(463
)

(160
)

Income before taxes

510

2,562

1,101

3,779

Income tax benefit (expense)

(127
)

95

(281
)

44

Net income

383

2,657

820

3,823

Income tax (benefit) expense

127

– 95

281

– 44

Interest (income) expense

156

120

634

160

Depreciation and amortization

583

776

2,191

1,559

Non-cash stock based compensation

86

41

428

342

Adjusted EBITDA*

$
1,335

$
3,499

$
4,354

$
5,840

*Adjusted EBITDA is earnings before interest, taxes, depreciation and amortization and non-cash stock-based compensation

BALANCE SHEETS

December 31,

2016

December 31,

2015

(In thousands)

Total current assets

$
25,083

$
18,754

Total assets

$
57,381

$
50,418

Total current liabilities

$
25,650

$
22,450

Total stockholders’ equity

$
12,911

$
11,741

Except for historical information contained in this report, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this report, words such as “anticipates,” “believes,” “could,” “estimates,” “expects,” “may,” “plans,” “potential,” and “intends,” and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company’s management, as well as assumptions made by and information currently available to the Company’s management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the effect of the dramatic changes taking place in IT and healthcare; continuation of the GEHC agreements; the impact of competitive technology and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in the conduct of clinical trials and other product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; and the risk factors reported from time to time in the Company’s SEC reports. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.

Investor Contact:

Michael J. Beecher
Investor Relations
Phone: 516-508-5840
Email: mbeecher@vasocorporation.com

SOURCE: Vaso Corporation

ReleaseID: 458470